Publication:
Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa

Simple item page
dc.contributor.authorContreras-Gómez, María José
dc.contributor.authorMartínez, José Rodrigo Waldemar
dc.contributor.authorRivas Jiménez, Lina María
dc.contributor.authorRiquelme-Neira, Roberto
dc.contributor.authorUgalde, Juan A.
dc.contributor.authorWozniak, Aniela
dc.contributor.authorGarcía, Patricia
dc.contributor.authorMunita, Jose M.
dc.contributor.authorOlivares-Pacheco, Jorge
dc.contributor.authorAlcalde-Rico, Manuel
dc.date.accessioned2023-07-11T16:57:06Z
dc.date.available2023-07-11T16:57:06Z
dc.date.issued2022
dc.description.abstractCarbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of beta-lactam with a beta-lactamase inhibitor. The most used combinations against P. aeruginosa are ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T). Although mechanisms leading to CZA and C/T resistance have already been described, among which are the resistance-nodulation-division (RND) efflux pumps, the role that these extrusion systems may play in CZA, and C/T baseline susceptibility of clinical isolates remains unknown. For this purpose, 161 isolates of non-carbapenemase-producing (Non-CP) CRPA were selected, and susceptibility tests to CZA and C/T were performed in the presence and absence of the RND efflux pumps inhibitor, Phenylalanine-arginine β-naphthylamide (PAβN). In the absence of PAβN, C/T showed markedly higher activity against Non-CP-CRPA isolates than observed for CZA. These results were even more evident in isolates classified as extremely-drug resistant (XDR) or with difficult-to-treat resistance (DTR), where CZA decreased its activity up to 55.2% and 20.0%, respectively, whereas C/T did it up to 82.8% (XDR), and 73.3% (DTR). The presence of PAβN showed an increase in both CZA (37.6%) and C/T (44.6%) activity, and 25.5% of Non-CP-CRPA isolates increased their susceptibility to these two combined antibiotics. However, statistical analysis showed that only the C/T susceptibility of Non-CP-CRPA isolates was significantly increased. Although the contribution of RND activity to CZA and C/T baseline susceptibility was generally low (two-fold decrease of minimal inhibitory concentrations [MIC]), a more evident contribution was observed in a non-minor proportion of the Non-CP-CRPA isolates affected by PAβN [CZA: 25.4% (15/59); C/T: 30% (21/70)]. These isolates presented significantly higher MIC values for C/T. Therefore, we conclude that RND efflux pumps are participating in the phenomenon of baseline susceptibility to CZA and, even more, to C/T. However, the genomic diversity of clinical isolates is so great that deeper analyzes are necessary to determine which elements are directly involved in this phenomenon.
dc.description.versionVersión publicada
dc.identifier.citationContreras-Gómez MJ, Martinez JRW, Rivas L, Riquelme-Neira R, Ugalde JA, Wozniak A, García P, Munita JM, Olivares-Pacheco J, Alcalde-Rico M. Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa. Front Pharmacol. 2022 Oct 3;13:1007162. doi: 10.3389/fphar.2022.1007162.
dc.identifier.doihttps://doi.org/10.3389/fphar.2022.1007162
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7698
dc.language.isoen
dc.subjectCeftazidime/avibactam
dc.subjectCefotolozane/tazobactam
dc.subjectRND efflux pump
dc.subjectBaseline susceptibility
dc.subjectCarbapenem resistant
dc.subjectPseudomonas aeruginosa
dc.titleRole of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceFrontiers in Pharmacology
dspace.entity.typePublication
relation.isAuthorOfPublication2bf16b44-04d3-45fe-8dd0-dafa6322ca94
relation.isAuthorOfPublicationec52b0bf-d0bc-4844-9531-eca4a65f2b8e
relation.isAuthorOfPublication.latestForDiscoveryec52b0bf-d0bc-4844-9531-eca4a65f2b8e

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fphar-13-1007162.pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services